The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion
Open accessAbstract
Significance: Preexisting neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved challenge that restricts patient enrollment in gene therapy clinical trials using recombinant AAV vectors. To tackle this problem, we developed a structure-guided approach to evolve AAV variants with altered antigenic footprints that cannot be recognized by preexisting antibodies. These proof-of-principle studies demonstrate that synthetic AAV variants can be evolved to evade neutralizing sera from different species—mice, nonhuman primates, and humans—without compromising yield and transduction efficiency or altering tropism. Our approach provides a roadmap for engineering any AAV strain to evade NAbs in prospective patients for human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modifications in the NAb recognition sites can enhance transduction efficiency [190–193].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [191]
In the citing paper
“Capsid engineering for capsids with resistance to antibodies can be performed through rational design (82 -88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“based on understanding of the epitope responsible for antibody binding, mutations and insertions were introduced to disrupt antibody binding and thus generate novel capsids with reduced antibody af fi nity (82, 87 -89).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“A novel capsid CAM130 had reduced NAb af fi nity against AAV1, but maintained comparable titer, transduction ef fi ciency, and tissue tropism (88).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [88]
In the citing paper
“Variants developed based on this analysis required 2-to 16-fold higher antibodies for neutralization compared to their parental serotype [89].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [89]
Citations
Cites
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
A viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392
Wu, Z., Miller, E., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00895-06 · Cited by 328
Self-citationIn Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Chicoine, L., Montgomery, C., Bremer, W., Shontz, K., Griffin, D., Heller, K., Lewis, S., Malik, V, Grose, W., Shilling, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.244 · Cited by 167
Tseng, Y.-S., & Agbandje‐McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 153
Self-citationB-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Metadata
- Authors
- Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Gene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599;
- University of Florida (US)
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32611;
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2017-05-30
- Volume
- 114
- Issue
- 24
- Pages
- E4812-E4821
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC5474820
- OpenAlex
- W2617246817
- Cited by
- 210
- References
- 30
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 19 · 2023: 30 · 2022: 29 · 2021: 25 · 2020: 26 · 2019: 21 · 2018: 15 · 2017: 7
- FWCI
- 12.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL089221, P01HL112761)
- HHS | NIH | National Institute of General Medical Sciences (R01GM082946, T32-GM008799)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- adeno-associated virus, neutralizing antibodies, immune evasion, AAV1, gene therapy vectors, rhesus monkeys, transduction efficiency
- MeSH terms
- Dependovirus, Amino Acid Sequence, Animals, Antibodies, Viral, Antigen-Antibody Complex, Antigenic Variation, Antigens, Viral, Female, Genetic Vectors, Humans, Macaca mulatta, Mice, Inbred BALB C, Models, Molecular, Serotyping, Genetic Therapy, Directed Molecular Evolution, Capsid Proteins, Mice, Immune Evasion, Antibodies, Neutralizing, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. https://app.cochat.ai/papers/10.1073/pnas.1704766114
- The paper
- Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017). Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1704766114
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.